Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase - PubMed

8 hours ago

Ocrelizumab discontinuation due to safety concerns was associated with higher annualized relapse rates compared to continuation.
No significant difference in time to first relapse was observed between switchers and continuers.
Trends toward increased risk of confirmed disability worsening at 24 weeks and progression independent of relapse activity were noted in switchers.
The study highlights the importance of maintaining therapeutic intensity and monitoring during treatment transitions.

Hasty Briefsbeta